FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200303223> ?p ?o ?g. }

• W4200303223 endingPage "363" @default.
• W4200303223 startingPage "351" @default.
• W4200303223 abstract "Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured with R-CHOP. Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, which is ubiquitously expressed on the surface of malignant B cells.We conducted a double-blind, placebo-controlled, international phase 3 trial to evaluate a modified regimen of R-CHOP (pola-R-CHP), in which vincristine was replaced with polatuzumab vedotin, as compared with standard R-CHOP, in patients with previously untreated intermediate-risk or high-risk DLBCL. Patients 18 to 80 years of age were randomly assigned in a 1:1 ratio to receive six cycles of either pola-R-CHP or R-CHOP, plus two cycles of rituximab alone. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival and safety.Overall, 879 patients underwent randomization: 440 were assigned to the pola-R-CHP group and 439 to the R-CHOP group. After a median follow-up of 28.2 months, the percentage of patients surviving without progression was significantly higher in the pola-R-CHP group than in the R-CHOP group (76.7% [95% confidence interval (CI), 72.7 to 80.8] vs. 70.2% [95% CI, 65.8 to 74.6] at 2 years; stratified hazard ratio for progression, relapse, or death, 0.73 by Cox regression; 95% CI, 0.57 to 0.95; P = 0.02). Overall survival at 2 years did not differ significantly between the groups (88.7% [95% CI, 85.7 to 91.6] in the pola-R-CHP group and 88.6% [95% CI, 85.6 to 91.6] in the R-CHOP group; hazard ratio for death, 0.94; 95% CI, 0.65 to 1.37; P = 0.75). The safety profile was similar in the two groups.Among patients with previously untreated intermediate-risk or high-risk DLBCL, the risk of disease progression, relapse, or death was lower among those who received pola-R-CHP than among those who received R-CHOP. (Funded by F. Hoffmann-La Roche/Genentech; POLARIX ClinicalTrials.gov number, NCT03274492.)." @default.
• W4200303223 created "2021-12-31" @default.
• W4200303223 creator A5003078312 @default.
• W4200303223 creator A5003727895 @default.
• W4200303223 creator A5004550999 @default.
• W4200303223 creator A5007117385 @default.
• W4200303223 creator A5009487344 @default.
• W4200303223 creator A5012675709 @default.
• W4200303223 creator A5013007045 @default.
• W4200303223 creator A5019218337 @default.
• W4200303223 creator A5020699813 @default.
• W4200303223 creator A5024269299 @default.
• W4200303223 creator A5026641386 @default.
• W4200303223 creator A5027118202 @default.
• W4200303223 creator A5029209393 @default.
• W4200303223 creator A5033029228 @default.
• W4200303223 creator A5038526399 @default.
• W4200303223 creator A5039994927 @default.
• W4200303223 creator A5045486705 @default.
• W4200303223 creator A5046659441 @default.
• W4200303223 creator A5049461398 @default.
• W4200303223 creator A5051605599 @default.
• W4200303223 creator A5061466414 @default.
• W4200303223 creator A5061916244 @default.
• W4200303223 creator A5063072439 @default.
• W4200303223 creator A5066795023 @default.
• W4200303223 creator A5082085036 @default.
• W4200303223 creator A5082892912 @default.
• W4200303223 creator A5084148942 @default.
• W4200303223 creator A5086354986 @default.
• W4200303223 creator A5088476247 @default.
• W4200303223 creator A5090424441 @default.
• W4200303223 creator A5091483542 @default.
• W4200303223 creator A5091800861 @default.
• W4200303223 date "2022-01-27" @default.
• W4200303223 modified "2023-10-17" @default.
• W4200303223 title "Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma" @default.
• W4200303223 cites W1966714873 @default.
• W4200303223 cites W199065211 @default.
• W4200303223 cites W2032208962 @default.
• W4200303223 cites W2050100708 @default.
• W4200303223 cites W2058015212 @default.
• W4200303223 cites W2069832110 @default.
• W4200303223 cites W2089197481 @default.
• W4200303223 cites W2119147717 @default.
• W4200303223 cites W2127018518 @default.
• W4200303223 cites W2145453495 @default.
• W4200303223 cites W2147246240 @default.
• W4200303223 cites W2147757009 @default.
• W4200303223 cites W2166900358 @default.
• W4200303223 cites W2167556523 @default.
• W4200303223 cites W2171356556 @default.
• W4200303223 cites W2310716991 @default.
• W4200303223 cites W2518731208 @default.
• W4200303223 cites W2605767476 @default.
• W4200303223 cites W2742627598 @default.
• W4200303223 cites W2744261860 @default.
• W4200303223 cites W2754056099 @default.
• W4200303223 cites W2797584152 @default.
• W4200303223 cites W2801763724 @default.
• W4200303223 cites W2807744826 @default.
• W4200303223 cites W2845112623 @default.
• W4200303223 cites W2903278833 @default.
• W4200303223 cites W2903308035 @default.
• W4200303223 cites W2923453543 @default.
• W4200303223 cites W2927138762 @default.
• W4200303223 cites W2934686121 @default.
• W4200303223 cites W2946486395 @default.
• W4200303223 cites W2984927918 @default.
• W4200303223 cites W3045506957 @default.
• W4200303223 cites W3132205831 @default.
• W4200303223 cites W3134205746 @default.
• W4200303223 cites W4205736005 @default.
• W4200303223 cites W4292528167 @default.
• W4200303223 doi "https://doi.org/10.1056/nejmoa2115304" @default.
• W4200303223 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34904799" @default.
• W4200303223 hasPublicationYear "2022" @default.
• W4200303223 type Work @default.
• W4200303223 citedByCount "191" @default.
• W4200303223 countsByYear W42003032232022 @default.
• W4200303223 countsByYear W42003032232023 @default.
• W4200303223 crossrefType "journal-article" @default.
• W4200303223 hasAuthorship W4200303223A5003078312 @default.
• W4200303223 hasAuthorship W4200303223A5003727895 @default.
• W4200303223 hasAuthorship W4200303223A5004550999 @default.
• W4200303223 hasAuthorship W4200303223A5007117385 @default.
• W4200303223 hasAuthorship W4200303223A5009487344 @default.
• W4200303223 hasAuthorship W4200303223A5012675709 @default.
• W4200303223 hasAuthorship W4200303223A5013007045 @default.
• W4200303223 hasAuthorship W4200303223A5019218337 @default.
• W4200303223 hasAuthorship W4200303223A5020699813 @default.
• W4200303223 hasAuthorship W4200303223A5024269299 @default.
• W4200303223 hasAuthorship W4200303223A5026641386 @default.
• W4200303223 hasAuthorship W4200303223A5027118202 @default.
• W4200303223 hasAuthorship W4200303223A5029209393 @default.
• W4200303223 hasAuthorship W4200303223A5033029228 @default.
• W4200303223 hasAuthorship W4200303223A5038526399 @default.
• W4200303223 hasAuthorship W4200303223A5039994927 @default.

• next